

WO 01/24780

PCT/IN00/00079

We claim:

1. A pharmaceutical composition in form of a soft gel capsule resistant to gastric juice and soluble in intestine useful for the treatment of duodenal ulcers and related ailments which comprises of a gelatin shell resistant to gastric juice and soluble in intestine having an enteric polymer mixed into gelatin in the form of free acid or its salt and the capsule incorporating a composition comprising of benzimidazole derivative, a hydrophobic oily substance or a mixture of such oily substances, an alkaline inert reacting material, a suspending agent, a surface active agent and / or a solublising agent; wherein the capsules are insoluble in aqueous medium up to a pH of 5.5 but quickly dissolving above pH of 6.0.
2. A pharmaceutical composition as claimed in claim 1 wherein the benzimidazole derivative, is selected from medicaments such as omeprazole, lansoprazole, pantoprazole, timoprazole and the like and the amount present in the formulation is equivalent to one unit dose of selected benzimidazole derivative.
3. A pharmaceutical composition as claimed in claim[s] 1 [& 2] wherein the enteric polymer employed for coating the gelatin shell is selected from polymers such as hydroxypropyl methyl cellulose phthalate, alkyl methacrylate and methacrylic acid copolymers, polyvinyl acetate phthalate and the like in the form of free acid or their ammonia or alkali metal salts and the amount employed ranging from 5.0 to 40.0 percent, preferably 5.0 to 25.0 percent by weight, with reference to the dried shell.
4. A pharmaceutical composition as claimed in claim[s] 1 [to 3] wherein the benzimidazole derivative in the formulation is suspended / solubilised in a hydrophobic oily substance selected from fats and oils of vegetable origin such as sesame oil, corn oil, maize oil, soybean oil, sunflower oil, arachis oil, gingly oil and the like; animal origin such as fish oil, pig oil, beef oil and the like; esters of straight chain aliphatic oils such as Sunsoft 700 P-2 (Taiho chemical company) Panasete 810 (Nippon oils and Fats); hydrogenated vegetable oils or a mixture thereof and the amount of hydrophobic oily substance used ranging from 50.0 to 80.0 percent by weight, with reference to the contents filled in capsules.

5 ~~5.~~ A pharmaceutical composition as claimed in claim~~5~~ 1 ~~[to 4]~~ wherein
substances such as ascolloidal silicon dioxide, polyvinylpyrrolidone are
used as dispersing agents in an amount ranging from 0.5 to 20.0 percent
preferably 1.0 to 10.0 percent by weight and materials such as glyceryl
monostearate, lecithin, polyoxyethylene castor oil derivative such as
10 Cremophor RH 40, Cremophor EL (BASF) polyoxyethylene sorbitan
fatty acid esters, sodium lauryl sulphate, docusate sodium and the like
are used as surface active agent and / or a solublising agent and the
amount of surface active agent and/or solublising agent ranging from 2.0
to 20.0 percent, preferably 5.0 to 15.0 percent by weight, with reference
15 to the contents filled in capsule.

~~6.~~ A pharmaceutical composition as claimed in claim~~5~~ 1 ~~[to 5]~~ wherein
materials such as the sodium, potassium, calcium, magnesium and
aluminium salts of phosphoric acid, carbonic acid, citric acid, other
20 suitable organic or inorganic acids; substances used in antacid
preparations; meglumine; triethanolamine and the like are used as
alkaline inert reacting materials and the amount ranging from 5.0 to
40.0 percent, preferably 10.0 to 25.0 percent by weight, with reference
to the contents filled in capsule.

25 ~~7.~~ A pharmaceutical composition as claimed in claim~~5~~ 1 ~~[to 6]~~ wherein
the soft gel capsules are treated with a gelatin cross linking agent such as
formaldehyde, glutaraldehyde, crotonaldehyde, 1,2-phthalic acid
aldehyde, 1,3-phthalic acid aldehyde, 1,4-phthalic acid aldehyde;
30 carboimides such as 1-ethyl-3-[2-morpholinyl-(4)-ethyl]-carboimide-
metho-P-toluene-sulfonate and the like.

~~8.~~ A pharmaceutical composition as claimed in claim~~5~~ 1 ~~[to 7]~~ wherein
the soft gel capsules are treated with cold dilute solutions of acids
35 selected from hydrochloric acid, sulphuric acid, nitric acid, phosphoric
acid, citric acid, propionic acid, benzoic acid, oxalic acid, maleic acid,
fumaric acid and the like.

40 9. A process for the preparation of a pharmaceutical composition in the
form of a soft gel capsule resistant to gastric juice and soluble in
intestine useful for the treatment of duodenal ulcers and related ailments